{"schema_version":"secwatch.filing_event.v1","accession":"0001048477-23-000041","form_type":"8-K","ticker":"BMRN","cik":"0001048477","company_name":"BIOMARIN PHARMACEUTICAL INC","filed_at":"2023-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.026212+00:00","generated_at":"2026-06-09T01:54:45.945389+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BioMarin Q3 2023: revenue $581M (+15% YoY), VOXZOGO $123M (+155%), cuts ROCTAVIAN guidance","bullets":["Q3 total revenue $581.3M (+15% YoY), GAAP net income $40.4M vs loss $6.7M, GAAP diluted EPS $0.21 vs ($0.04).","VOXZOGO revenue $123.1M (+155% YoY); full-year guidance raised to $435-455M from $400-440M.","ROCTAVIAN revenue $0.8M; full-year guidance slashed to <$10M from $50-150M due to pricing delays.","Full-year 2023 total revenue guidance narrowed to $2.39-2.47B; Non-GAAP diluted EPS guided $1.90-2.05.","Management expects 2024 revenue to approach $3B; VOXZOGO age expansions in US and EU; hypochondroplasia trial to start."],"urls":{"canonical":"https://secwatch.observer/filing/0001048477-23-000041","json":"https://secwatch.observer/filing/0001048477-23-000041.json","markdown":"https://secwatch.observer/filing/0001048477-23-000041.md","text":"https://secwatch.observer/filing/0001048477-23-000041.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1048477/000104847723000041/0001048477-23-000041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1048477/000104847723000041/bmrn-20231101.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T01:54:45.945389+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"375709c22625f7998162df59f22419a456c1ca05","claim":"BIOMARIN PHARMACEUTICAL INC updated its full-year 2023 guidance (reaffirmed).","evidence_excerpt":"\"Results in the quarter drove double-digit revenue growth year-over-year and supports BioMarin’s full-year 2023 revenue and profitability objectives, set at the beginning of the year,\"","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1048477/000104847723000041/0001048477-23-000041-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full-year 2023"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"a00814250c1a0f9704821b8359b5f95aee366514","claim":"BIOMARIN PHARMACEUTICAL INC reported third quarter ended September 30, 2023 results: revenue $581.3 million, net income $40.4 million, EPS $0.21.","evidence_excerpt":"facilitate patient access, setting the stage for meaningful uptake of ROCTAVIAN in 2024.” Third Quarter Financial Highlights: • Total Revenues for the third quarter of 2023 were $581.3 million, an increase of 15% compared to the same period in 2022. The increase in Total Revenues was primarily attributed to the following: ◦ higher VOXZOGO sales volume due to new","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1048477/000104847723000041/0001048477-23-000041-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"$581.3 million"},{"label":"Net income","value":"$40.4 million"},{"label":"EPS","value":"$0.21"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}